for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Werewolf Therapeutics Inc

HOWL.OQ

Latest Trade

16.50USD

Change

0.25(+1.54%)

Volume

1,269

Today's Range

16.04

 - 

16.52

52 Week Range

11.26

 - 

23.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.25
Open
16.04
Volume
1,269
3M AVG Volume
0.47
Today's High
16.52
Today's Low
16.04
52 Week High
23.99
52 Week Low
11.26
Shares Out (MIL)
27.57
Market Cap (MIL)
449.63
Forward P/E
-2.64
Dividend (Yield %)
--

Latest Developments

More

Werewolf Therapeutics Reports Quarterly Loss Per Share Of $3.82

Werewolf Therapeutics Reports Second Quarter 2021 Financial Results And Business Update

Werewolf Therapeutics Says Net Loss Was $7.4 Million For Q1 2021, Compared To $3.8 Million For Same Period In 2020

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Werewolf Therapeutics Inc

Werewolf Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing a pipeline of cancer treatments. It is developing immuno-stimulatory therapeutics designed to act selectively within the tumor microenvironment to enhance the body’s immune response to cancer. Its PREDATOR platform is design to conditionally activate molecules that stimulate both adaptive and innate immunity with addressing the limitations of conventional proinflammatory immune therapies. The INDUKINETM molecules, is intended to selectively target the tumor microenvironment (TME). PREDATOR platform consists of protein engineering technologies which is used to generate INDUKINE molecules with multiple functional domains rationally engineered into a single protein to achieve the pharmaceutical profile. The Company using PREDATOR platform, have developed three initial product candidates: WTX-124, WTX-330 and WTX-613.

Industry

Business Services

Contact Info

1030 Massachusetts Avenue, Suite 210

CAMBRIDGE, MA

02138

United States

+1.617.9520555

https://werewolftx.com/

Executive Leadership

Luke B. Evnin

Independent Chairman of the Board

Daniel J. Hicklin

President, Chief Executive Officer, Director

Timothy W. Trost

Chief Financial Officer, Treasurer

Reid J. Leonard

Chief Operating Officer

Chulani Karunatilake

Chief Technology Officer

Key Stats

1.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-6.150
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.44
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up